New Methods Of Treatment Parkinson's Disease

New Methods Of Treatment Parkinson's Disease.
Parkinson's disability has no cure, but three speculative treatments may help patients cope with unpleasant symptoms and related problems, according to redesigned research. The research findings will be presented at the annual meeting of the American Academy of Neurology in San Diego from March 16 to 23, 2013. "Progress is being made to prolong our use of medications, originate new medications and to treat symptoms that either we haven't been able to treat effectively or we didn't cotton were problems for patients," said Dr Robert Hauser, professor of neurology and chairman of the University of South Florida Parkinson's Disease and Movement Disorders Center in Tampa. Parkinson's disease, a degenerative intelligence disorder, affects more than 1 million Americans.

It destroys valour cells in the brain that make dopamine, which helps control muscle movement. Patients sample shaking or tremors, slowness of movement, balance problems and a stiffness or rigidity in arms and legs. In one study, Hauser evaluated the remedy droxidopa, which is not yet approved for use in the United States, to alleviate patients who experience a rapid fall in blood pressure when they stand up, which causes light-headedness and dizziness. About one-fifth of Parkinson's patients have this problem, which is due to a lead balloon of the autonomic nervous pattern to release enough of the hormone norepinephrine when posture changes.

Hauser studied 225 people with this blood-pressure problem, assigning half to a placebo gathering and half to take droxidopa for 10 weeks. The downer changes into norepinephrine in the body. Those on the medicine had a two-fold decline in dizziness and lightheadedness compared to the placebo group. They had fewer falls, too, although it was not a statistically significant decline.

In a surrogate study, Hauser assessed 420 patients who knowledgeable a daily "wearing off" of the Parkinson's pharmaceutical levodopa, during which their symptoms didn't respond to the drug. He compared those who took exceptional doses of a new drug called tozadenant, which is not yet approved, with those who took a placebo.

All still took the levodopa. At the onset of the study, the patients had an average of six hours of "off time" a lifetime when symptoms reappeared. After 12 weeks, those on a 120-milligram or 180-milligram dose of tozadenant had about an hour less of "off time" each heyday than they had at the start of the study.